Sirnaomics Receives IND Clearance from the Taiwan Ministry of Health and Welfare for Phase I Clinical Study of RNAi Therapeutic STP705 for Liver Cancer Treatment

Corporate Breaking News

Home : Sirnaomics Receives IND Clearance from the Taiwan Ministry of Health and Welfare for Phase I Clinical Study of RNAi Therapeutic STP705 for Liver Cancer Treatment

Jul 26 2022	Sirnaomics Receives IND Clearance from the Taiwan Ministry of Health and Welfare for Phase I Clinical Study of RNAi Therapeutic STP705 for Liver Cancer Treatment
GAITHERSBURG, Md. and SUZHOU, China, July 26, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the Company has received regulatory...


Source:https://www.prnewswire.com:443/news-releases/sirnaomics-receives-ind-clearance-from-the-taiwan-ministry-of-health-and-welfare-for-phase-i-clinical-study-of-rnai-therapeutic-stp705-for-liver-cancer-treatment-301593046.html

Related News
» BSV BLOCKCHAIN ASSOCIATION PARTNERS WITH TIMECHAIN LABS TO HOST BLOCKCHAIN EVENT IN INDIA » Expanded Polystyrene Market Size for Packaging to Grow by USD 3.15 Bn, BASF SE, and Kaneka Corp. Among Key Vendors - Technavio